Menu
Recruiting NCT04579588

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

Observational Corona Virus Infection Flu Vaccine Immunity

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Flu shot.
Who it may be relevant to
Registry conditions: Corona Virus Infection, Flu Vaccine, Immunity. Basic parameters: 9 years — 64 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19 symptoms. Adults and children (age 9 to 64) who had been diagnosed with COVID-19 as well as controls without COVID-19 will be invited to participate in this study.

Interventions

  • Biological Flu shot
    All participants will receive a single shot of the flu vaccine

Primary outcome measures

  • Testing immunity to the flu vaccine over time [Time frame: 1 week]
  • Testing immunity to the flu vaccine over time [Time frame: 1 month]

Eligibility criteria

Inclusion criteria

  • Age 9 through 64 years
  • Diagnosed with COVID-19 at least 2 months prior enrollment
  • Patients with or without obesity, diabetes, chronic fatigue and/or long term COVID-19 symptoms
  • Patients without COVID-19 diagnosis for controls

Exclusion criteria

  • Received the influenza vaccine less than 4 months ago
  • Pregnant or lactating
  • Patients with special risks attendant to venipuncture
  • Use of immunomodulatory medications that may impact vaccine immune response per clinician's judgment
  • Contraindication to the flu vaccine
  • Immunodeficiency or autoimmune disease that may impact vaccine immune responses per clinician's judgement

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Case-control

Study locations

United States · 1 center
  • Stanford University — Palo Alto

Identifiers

NCT: NCT04579588 · IRB-58356 · 5U19AI057229-17

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗